Recruiting
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
NCT07440290· Phase 2/3· Cancer Research UK· Source
Contact: Sarah Danson, Dr
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Eli Lilly and Company· Source
Contact: Syed Hussain (principal investigator)
Recruiting
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
NCT05770544· Phase 2/3· Cancer Research UK· Source
Contact: Sarah Danson, Dr
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401· Phase 3· Pfizer· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· Phase 3· Hoffmann-La Roche· Source
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563· Phase 3· NovoCure GmbH· Source
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649· Phase 3· Amgen· Source
Recruiting
The Psychological Impact of GTN on Women Who Have Completed Chemotherapy Treatment
NCT06169644· Sheffield Teaching Hospitals NHS Foundation Trust· Source
Contact: Kamaljit Singh
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Contact: Tathagata Das (principal investigator)
Recruiting
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
NCT05770037· Phase 2/3· Cancer Research UK· Source
Contact: Sarah Danson, Dr
Recruiting
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
NCT05770102· Phase 2/3· Cancer Research UK· Source
Contact: Sarah Danson, Dr
Recruiting
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
NCT05786716· Phase 2/3· Cancer Research UK· Source
Contact: Sarah Danson, Dr
Recruiting
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
NCT05768178· Phase 2/3· Cancer Research UK· Source
Contact: Sarah Danson, Dr
Recruiting
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
NCT05722886· Phase 2/3· Cancer Research UK· Source
Contact: Sarah Danson, Dr
Recruiting
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
NCT04550104· Phase 1· University of Leeds· Source
Contact: Matthew Hatton (principal investigator)
Recruiting
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907· Phase 1/2· University of Birmingham· Source
Contact: Robin Young
Active, not recruiting
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
NCT04360941· Phase 1· Royal Marsden NHS Foundation Trust· Source
Recruiting
WIRE - Novel Treatments in Renal Cell Cancer
NCT03741426· Phase 2· CCTU- Cancer Theme· Source
Contact: Janet Brown (principal investigator)
Active, not recruiting
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
NCT03972488· Phase 3· Advanced Accelerator Applications· Source
Recruiting
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
NCT03740893· Phase 2· Institute of Cancer Research, United Kingdom· Source
Contact: Christophe Verstegen
Recruiting
Renal Adjuvant MultiPle Arm Randomised Trial
NCT03288532· Phase 3· University College, London· Source
Contact: Carmel Pezaro (principal investigator)
Active, not recruiting
Stereotactic Body Radiotherapy for the Treatment of OPD
NCT03256981· Phase 2/3· Institute of Cancer Research, United Kingdom· Source
Recruiting
Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer
NCT04050345· Royal Marsden NHS Foundation Trust· Source
Contact: Alice Dewdney (principal investigator)
Active, not recruiting
Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer
NCT02417662· University College, London· Source
Active, not recruiting
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
NCT02804815· Phase 3· University College, London· Source
Active, not recruiting
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
NCT02375204· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
NCT04116047· Phase 3· University of Birmingham· Source
Active, not recruiting
Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer
NCT01566240· Phase 3· University College, London· Source
Active, not recruiting
Prostate Advances in Comparative Evidence
NCT01584258· Phase 3· Royal Marsden NHS Foundation Trust· Source